Device Financing in 2006: Closing the Gap with Biopharma
This article was originally published in Start Up
Executive Summary
While device companies didn't raise as much in venture capital over the course of 2006 as their biopharma counterparts did, they did close the gap considerably.
You may also be interested in...
New Data Highlights Benefits, Risks of Obesity Surgery
Obesity has become an epidemic, with 30% of the U.S. population obese and an additional 35% overweight, including children and adolescents. Bariatric surgical procedures have skyrocketed in recent years, with hospital costs exceeding $1.2 billion, and good success rates. However, for certain groups, such as patients over 65, the risks of bariatric surgery may outweigh the benefits. Much needs to be done to address this troubling and growing public health problem.
EnteroMedics' Weighty Financing for Obesity
EnteroMedics recently earned the distinction of closing the second-largest financing for a private medical device company in 2006. Its success was undoubtedly due to the company's attractive position at the junction of two of the device industry's hottest markets: obesity and neuromodulation. EnteroMedics is developing an implantable impulse generator that it hopes will address multiple mechanisms in obesity.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”